Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

MDxI Launches LabFile Data Resource

Published: Friday, July 25, 2014
Last Updated: Thursday, July 24, 2014
Bookmark and Share
New standard for defining and targeting US clinical laboratory universe.

Market Diagnostics International LLC has announced the availability of IVD Insights™ LabFile, a data resource that sets a new standard for defining the US clinical laboratory universe and identifying target In Vitro Diagnostics (IVD) customers.

LabFile is a proprietary database that provides IVD manufacturers with accurate and comprehensive information on sites performing clinical tests, relying on clear and consistent definitions of laboratory categories and institutional affiliations.

LabFile is based on MDxI’s extensive site research and industry knowledge and is a highly informative tool for defining market opportunities and targets.

“Our work with IVD clients indicated that even sophisticated companies had incomplete, often conflicting information about existing customers, and they were struggling to accurately identify and target new customers. Many also were spending considerable resources to update and refine their CRM systems, often with unsatisfactory results,” commented Kathi McGregor, President and Managing Partner of MDxI.

McGregor continued, “LabFile was developed to address these issues. Over the past two years, we obtained input from manufacturers about what was missing in their own databases and then invested thousands of hours in developing LabFile, the most rigorously designed and compiled clinical laboratory database to date. We also are providing customers with quarterly updates to capture the ever-changing nature of the laboratory market.”

Unlike other industry data resources, which assume that the 200,000+ CLIA licenses equal an equivalent number of unique laboratories, LabFile takes into account the expansion of health care delivery networks and resulting consolidation of laboratory testing.

Currently, LabFile identifies and classifies nearly 14,000 verified sites for targeting out of the estimated 18,000 US labs performing moderate to high complexity IVD testing. The number of verified, profiled sites will continue to grow as the product is expanded, with such added details as identifying sites that perform only CLIA-waived testing.

Updated quarterly, LabFile is a valuable resource for cleaning, maintaining, and reconciling current CRM data or establishing new CRM systems.

Reports are easily segmented and targeted for specific purposes, using clearly defined and standardized classification of laboratory types, subtypes, and network affiliations.

Coupled with MDxI’s IVD Insights Reports, LabFile presents the clearest picture of the configuration and depth of the US IVD market available.

To learn more about IVD Insights™ LabFile, visit Booth #1679 at the 2014 AACC Annual Meeting in Chicago, IL, July 27-31, 2014.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos